Diagnosis

Lichen sclerosus

A chronic autoimmune dermatosis characterized by skin atrophy and hypopigmentation with genital and extragenital presentations.

Also known as: Balanitis xerotica obliterans, Kraurosis vulvae, Leukoplakia, Lichen sclerosis et atrophicus

Etiology

Cause [2qy]

Pathophysiology [2qy]

  1. Infiltration of activated T cells releasing IL-4 and TGF-β

  2. Activated fibroblasts producing significantly altered collagen leading to fibrosis

  3. Vascular damage by the decrease in the number of capillaries

Complications [2qy]

Epidemiology

Incidence per 100.000 [zt7][ybc][4cb][v1t][avs][hor]

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Dyspareunia, Dysuria, Phimosis, Pruritus

Clinical findings

None listed.

Anamneses

None listed.

Localized findings

Rash
Radiates
Genital
Lesion type
PapulePlaqueVesicleBullaLichenificationFissureErosionAtrophyScarStriaHypopigmentationHyperpigmentation
Lesion configuration
AnnularKoebner phenomenonLinear
Color
White
Associated symptom
Itch
Rash
Radiates
ThoraxAbdomenArmBackLower bodyCollumCaput
Lesion type
PapulePlaqueBullaLichenificationFissureErosionAtrophyScarStriaHypopigmentationHyperpigmentation
Lesion configuration
AnnularLinearKoebner phenomenon
Color
White
Associated symptom
Itch

Approach

Treatment

  1. Lifestyle changes: moisturizer, silk underwear, lubrication

  2. First-line therapy:

    • Potent topical steroids (clobetasol ointment) once or twice daily for 3 months [zt7][jsy]

  3. Second-line therapy:

    • Calcineurin inhibitors: tacrolimus and pimecrolimus

  4. Third-line therapies: [jsy]

    • Topical or oral retinoids

    • Steroid injections

    • Cyclosporin

    • Methotrexate or hydroxyurea

    • Hydroxychloroquine < 6.5 mg/kg based on ideal body weight

    • For extragenital lichen sclerosus: phototherapy

  5. If topical steroids fail in male patients --> circumcision [jsy]

  6. Delayed diagnosis or steroid resistance --> genital reconstruction to restore functionality

Differential diagnoses

Acrodermatitis chronica atrophicans, Albinism, Anetoderma, Atrophoderma, Balanitis circumscripta plasmacellularis, Balanitis xerotica obliterans, Basal cell carcinoma, Candidiasis, Cutaneous T-cell lymphoma, Eczema, Graft-versus-host disease, Idiopathic guttate hypomelanosis, Leukoplakia, Lichen nitidus, Lichen planus, Morphea, Paget's disease, Pinta, Psoriasis, Scleroderma, Squamous cell carcinoma, Systemic lupus erythematosus, Tinea versicolor, Vitiligo


References

[1] Chamli A, Souissi A. Lichen Sclerosus. [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538246/

[2] Jerkovic Gulin S, Lundin F, Eriksson O, Seifert O. Lichen Sclerosus-Incidence and Comorbidity: A Nationwide Swedish Register Study. J Clin Med. 2024 May 8;13(10):2761.

[3] Baandrup L, Hannibal CG, Hertzum-Larsen R, Kjær SK. Biopsy-verified vulvar lichen sclerosus: Incidence trends 1997-2022 and increased risk of vulvar squamous precancer and squamous cell carcinoma. Int J Cancer. 2024 Aug 1;155(3):501-507.

[4] Halonen P, Jakobsson M, Heikinheimo O, Gissler M, Pukkala E. Incidence of lichen sclerosus and subsequent causes of death: a nationwide Finnish register study. BJOG. 2020 Jun;127(7):814-819.

[5] Bleeker MC, Visser PJ, Overbeek LI, van Beurden M, Berkhof J. Lichen Sclerosus: Incidence and Risk of Vulvar Squamous Cell Carcinoma. Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1224-30.

[6] De Luca DA, Papara C, Vorobyev A, Staiger H, Bieber K, Thaçi D, Ludwig RJ. Lichen sclerosus: The 2023 update. Front Med (Lausanne). 2023 Feb 16;10:1106318.

[7] Choudhary C, Beazley R, Uppal E, Kravvas G, Bunker C. The age-related incidence of male genital lichen sclerosus is triphasic. Skin Health and Disease. 2024. e447.

[8] http://emedicine.medscape.com/article/1123316; [Medscape]

[9] [Clinical Dermatology 4.th Edition by Weller, Hunter, Savin and Dahl]

Scroll to top